Actym Therapeutics, Inc.

Targeting intractable immune pathways in the tumor microenvironment

Add To Watchlist
General Information
Company Name
Actym Therapeutics, Inc.
Founded Year
2017
Location (Offices)
Berkeley, United States +1
Founders / Decision Makers
Christopher Thanos - President, CEO, and Cofounder Tom Smart - Chief Executive Officer and Board Member
Number of Employees
12
Industries
Biotechnology, Medical Devices
Funding Stage
Series A
Social Media

Actym Therapeutics, Inc. - Company Profile

Actym Therapeutics, Inc. is a cutting-edge biotech company that focuses on the discovery and development of novel immuno-oncology therapies. Founded in 2017 and headquartered in the United States, Actym Therapeutics is dedicated to targeting intractable immune pathways in the tumor microenvironment. The company's recent milestone includes a significant $25.50M Series A investment led by Illumina Ventures, Panacea Venture, Boehringer Ingelheim Venture Fund, JLo Ventures, and GKCC on 18 October 2023. Actym Therapeutics' relentless focus on leveraging biotechnology and medical devices for breakthroughs in cancer treatment positions it as a compelling prospect for venture capital investment.

Taxonomy: immuno-oncology, biotech, cancer therapy, STACT, microbial-based therapy, preclinical studies, solid tumors, immune cells, immuno-modulatory payloads, Series A financing, Boehringer-Ingelheim Venture Fund, Panacea Venture Healthcare, Illumina Ventures, Korea Investment Partners, JLO Ventures

Funding Rounds & Investors of Actym Therapeutics, Inc. (3)

View All
Funding Stage Amount No. Investors Investors Date
Series A $25.50M 5
Illumina Ventures, investor in Actym Therapeutics, Inc.'s Series A round Panacea Venture, investor in Actym Therapeutics, Inc.'s Series A round
Boehringer Ingelheim Venture Fund, JLo Ventures +1 		18 Oct 2023
Series A $34.00M 5
Korea Investment Partners, investor in Actym Therapeutics, Inc.'s Series A round Illumina Ventures, investor in Actym Therapeutics, Inc.'s Series A round Panacea Venture, investor in Actym Therapeutics, Inc.'s Series A round
JLo Ventures, Boehringer Ingelheim Venture Fund 		27 Apr 2020
Seed Round Unknown - 01 Nov 2017

Latest News of Actym Therapeutics, Inc.

View All

No recent news or press coverage available for Actym Therapeutics, Inc..

Similar Companies to Actym Therapeutics, Inc.

View All
Elpis Biopharmaceuticals - Similar company to Actym Therapeutics, Inc.
Elpis Biopharmaceuticals New Treatments. New Hope.
EXUMA Biotech - Similar company to Actym Therapeutics, Inc.
EXUMA Biotech
Neukio Biotherapeutics - Similar company to Actym Therapeutics, Inc.
Neukio Biotherapeutics Neukio Biotherapeutics focuses on development of next generation allogenic cell therapies via the iPSC-CAR-NK axis.
MedXCell SA - Similar company to Actym Therapeutics, Inc.
MedXCell SA The Cell Therapy Venture Builder
Agenus - Similar company to Actym Therapeutics, Inc.
Agenus
Circle Decoration Circle Decoration

Want to dive deeper into Actym Therapeutics, Inc.? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now